progression-free survival

Arvinas and Pfizer secure FDA approval for VEPPANU, the first PROTAC protein degrader, for ESR1-mutated breast cancer based on Phase 3 data showing 43% progression-risk reduction.

Pfizer's ELREXFIO cancer therapy shows superior efficacy in Phase 3 myeloma trial, but stock declines amid analyst skepticism about growth prospects.

Merck shares dropped 4% after Phase 3 cancer trial failure, but FDA approval of HIV treatment Idvynso provided partial offset.

Eli Lilly reports fourth positive Phase 3 trial for Jaypirca in chronic lymphocytic leukemia, positioning drug for label expansion ahead of competitive launches.

$IDYA's darovasertib-crizotinib combination doubled progression-free survival in metastatic uveal melanoma versus standard care, with FDA submission planned for late 2026.

Bristol Myers wins FDA approval for Opdivo plus chemotherapy in untreated Hodgkin lymphoma. Stock declined 1.33% despite clinical success in Study CA209-8UT.

Pfizer reports positive Phase 2 data for atirmociclib in metastatic breast cancer, meeting survival endpoints. Company also gains FDA approval for Braftovi in colorectal cancer.

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.

Celcuity's gedatolisib achieved 76% risk reduction in advanced breast cancer with PIK3CA wild-type mutations; FDA Priority Review decision expected July 2026.

Roche's giredestrant failed to meet primary endpoint in Phase 3 breast cancer trial, causing 5% stock decline. Company plans adjuvant trial readout in 2027.

Pfizer's Braftovi receives full FDA approval for treating BRAF-mutated metastatic colorectal cancer when combined with cetuximab and chemotherapy, based on Phase 3 trial data.

Pfizer's Braftovi regimen met primary endpoints in Phase 3 colorectal cancer trial, showing significant improvements in progression-free survival versus standard chemotherapy in BRAF-mutated patients.